AI Article Synopsis
- A phase-II study evaluated the effectiveness and safety of atezolizumab combined with obinutuzumab in relapsed/refractory mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM), and with rituximab in marginal zone lymphoma (MZL).
- Objective response rates were 16.7% for MCL, 42.9% for MZL, and no responses for WM, with median response durations of 6.8 months for MCL and not reached for MZL.
- Treatment-emergent adverse events (TEAEs) were common across patient groups (93.3% in MCL, 95.2% in MZ
Article Abstract
We report efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab (eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with relapsed/refractory mantle cell lymphoma (MCL, = 30) or Waldenström's macroglobulinemia (WM, = 4), and in combination with rituximab in patients with marginal zone lymphoma (MZL, = 21). All patients received atezolizumab monotherapy as maintenance for ≤10 cycles. Objective response rates at end of induction were 16.7% (MCL) and 42.9% (MZL), with no responses in WM. Median duration of response was 6.8 months (range 5.7-not estimable) for MCL and not reached for MZL. Treatment-emergent adverse events (TEAEs) occurred in 93.3%, 95.2% and 100% of MCL, MZL and WM patients, respectively. One fatal TEAE (pneumonia) occurred in each of the MCL and MZL groups. Biomarker analysis highlighted the importance of characterizing the immune environment to optimize efficacy of immunotherapy regimens. EudraCT: 2016-003579-22.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2021.2015765 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!